Letters |1 October 2013
Aspirin Versus Low-Molecular-Weight Heparin After Total Hip Arthroplasty
David R. Anderson, MD; Michael J. Dunbar, MD; Susan R. Kahn, MD
David R. Anderson, MD
From Dalhousie University, Halifax, Nova Scotia, Canada; and McGill University, Montréal, Québec, Canada.
Michael J. Dunbar, MD
Susan R. Kahn, MD
Potential Conflicts of Interest: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M12-2191.
IN RESPONSE:
We thank Drs. Granziera and Cohen for their comments about our recent EPCAT (Extended Prophylaxis Comparing Low Molecular Weight Heparin to Aspirin in Total Hip Arthroplasty) study, which provides further evidence about the benefit of aspirin for the prevention of VTE after total hip arthroplasty (1). As Drs. Granziera and Cohen point out, patients randomly assigned to receive either low-molecular-weight heparin or aspirin had low rates of major risk factors for VTE and bleeding. More than 90% of the participants had none of the major risk factors cited for thromboembolism, and more than 98% had no history...
Anderson DR, Dunbar MJ, Kahn SR. Aspirin Versus Low-Molecular-Weight Heparin After Total Hip Arthroplasty. Ann Intern Med. 2013;159:502–503. doi: 10.7326/0003-4819-159-7-201310010-00018
Aspirin Versus Low-Molecular-Weight Heparin for Extended Venous Thromboembolism Prophylaxis After Total Hip Arthroplasty: A Randomized Trial